Intrexon | XON - Operating Expenses


Intrexon reported $61.56M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agenus USD 19.81M 293.94M Dec/2025
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 53.32M 13.68M Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Veracyte USD 116M 7.24M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025